Efficacy and Safety of Middle Meningeal Artery Embolization for Treatment of Intractable Migraine

Korábbi kezelés

• Patients scheduled for surgery within 90 days.
• Participants who had participated in clinical studies of other drugs or medical devices before enrollment and did not meet the primary study endpoint time limit.

Más betegség

• Patients with cervical spondylosis and secondary headaches such as otogenic, nasal, and odontogenic patients with a history of trigeminal autonomic headache, other definite causes of headache, or secondary headache.
• History of contrast agent allergy.
• The patient had a clear history of allergies to embolic materials such as Nitinol alloy, cobalt-based alloy, and platinum-tungsten alloy.
• Patient was allergic to the contrast agent.
• Patients with other diseases limit their participation in the study, cannot follow up, or affect the scientific integrity of the study.
• Patients have clotting disorders or are on anticoagulant therapy.
• Patients have a history of opioid addiction.

Egyéb

• Patients without suitable vascular access.
• The life expectancy of patients is less than 12 months.
• Lactating or pregnant women, or patients with a fertility plan within 1 year.
• The clinical status of the patient was extremely poor, with an mRS Score ≥4.
• The investigator judged that the patient had poor compliance and could not complete the study as required.
• Researchers believe that patients who are not suitable to participate in this trial.

• Voluntary written informed consent.
• Age 18~80 years old (inclusive), regardless of gender.
• Migraine was diagnosed by clinicians, according to The International Classification of Headache Disorders,3rd Edition
• Patients with intractable migraine or refractory headache with migraine duration of more than 3 months and recurring migraine in the past 90 days before screening.
• Patients who take two or more drugs are not satisfied with the therapeutic effect, the side effects of drug treatment are difficult to tolerate or have contraindications.
• Headache frequency should be confirmed within 30 days before screening.
• Patients with good compliance, willing and able to follow the requirements of treatment and follow-up observation.